Literature DB >> 8366859

Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen.

M Q Xia1, G Hale, H Waldmann.   

Abstract

CAMPATH-1 antibodies recognise a unique molecule on human lymphocytes and are unusually efficient at causing cell lysis with homologous complement. They have been successfully used for lymphocyte depletion in vivo in a variety of diseases. The antigen is a small glycosylphosphatidylinositol (GPI)-anchored glycoprotein with a mature peptide comprising only 12 amino acids and one N-linked glycosylation site at Asn3. The antigenic epitope is found in a proteolytic fragment containing the C-terminal tripeptide and the GPI anchor. Both the native and deglycosylated antigen as well as the proteolytic fragment can be reincorporated into various target cells, conferring sensitivity to lysis by CAMPATH-1 antibodies. These results imply that the special feature of the antigen which makes it a good target does not reside in the N-linked sugar or the first nine amino acids: instead they support the hypothesis that the proximity of the antigenic epitope to the cell membrane is more important.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8366859     DOI: 10.1016/0161-5890(93)90155-5

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  23 in total

Review 1.  Targeted therapy for chronic lymphocytic leukemia: current status and future directions.

Authors:  Jon E Arnason; Jennifer R Brown
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

2.  Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro.

Authors:  Evis Havari; Michael J Turner; Juanita Campos-Rivera; Srinivas Shankara; Tri-Hung Nguyen; Bruce Roberts; William Siders; Johanne M Kaplan
Journal:  Immunology       Date:  2014-01       Impact factor: 7.397

3.  Caspase-8 polymorphisms result in reduced Alemtuzumab-induced T-cell apoptosis and worse survival after transplantation.

Authors:  B E Shaw; F Lee; S Krishnamurthy; J L Byrne; C Seedhouse; N P Mayor; H Maldonado-Torres; A Saudemont; S G E Marsh; J A Madrigal; N H Russell
Journal:  Bone Marrow Transplant       Date:  2014-10-27       Impact factor: 5.483

Review 4.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

5.  HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis.

Authors:  Tom van Meerten; Henk Rozemuller; Samantha Hol; Petra Moerer; Mieke Zwart; Anton Hagenbeek; Wendy J M Mackus; Paul W H I Parren; Jan G J van de Winkel; Saskia B Ebeling; Anton C Martens
Journal:  Haematologica       Date:  2010-09-17       Impact factor: 9.941

Review 6.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

7.  Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.

Authors:  Liuyan Jiang; Constance M Yuan; Julia Hubacheck; John E Janik; Wyndham Wilson; John C Morris; Gregory A Jasper; Maryalice Stetler-Stevenson
Journal:  Br J Haematol       Date:  2009-02-19       Impact factor: 6.998

Review 8.  Antibody engineering to develop new antirheumatic therapies.

Authors:  John D Isaacs
Journal:  Arthritis Res Ther       Date:  2009-05-19       Impact factor: 5.156

9.  Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use.

Authors:  Jeremy L Warner; Jon E Arnason
Journal:  Ther Adv Hematol       Date:  2012-12

Review 10.  Alemtuzumab in stem cell transplantation.

Authors:  Geoff Hale
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.